Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution.

Williams SM, Sumstad D, Kadidlo D, Curtsinger J, Luo X, Miller JS, McKenna DH Jr.

Transfusion. 2018 Jun;58(6):1458-1467. doi: 10.1111/trf.14564. Epub 2018 Mar 12.

2.

Impact of starting material (fresh versus cryopreserved marrow) on mesenchymal stem cell culture.

Kaplan A, Sackett K, Sumstad D, Kadidlo D, McKenna DH.

Transfusion. 2017 Sep;57(9):2216-2219. doi: 10.1111/trf.14192. Epub 2017 Jun 26.

PMID:
28653392
3.

Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials.

McKenna DH Jr, Sumstad D, Kadidlo DM, Batdorf B, Lord CJ, Merkel SC, Koellner CM, Curtsinger JM, June CH, Riley JL, Levine BL, Miller JS, Brunstein CG, Wagner JE, Blazar BR, Hippen KL.

Cytotherapy. 2017 Feb;19(2):250-262. doi: 10.1016/j.jcyt.2016.10.011. Epub 2016 Nov 22.

4.

Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft.

Wagner JE Jr, Brunstein CG, Boitano AE, DeFor TE, McKenna D, Sumstad D, Blazar BR, Tolar J, Le C, Jones J, Cooke MP, Bleul CC.

Cell Stem Cell. 2016 Jan 7;18(1):144-55. doi: 10.1016/j.stem.2015.10.004. Epub 2015 Dec 5.

5.

Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.

Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, Curtsinger J, Verneris MR, MacMillan ML, Levine BL, Riley JL, June CH, Le C, Weisdorf DJ, McGlave PB, Blazar BR, Wagner JE.

Blood. 2016 Feb 25;127(8):1044-51. doi: 10.1182/blood-2015-06-653667. Epub 2015 Nov 12.

6.

Clinical mesenchymal stromal cell products undergo functional changes in response to freezing.

Pollock K, Sumstad D, Kadidlo D, McKenna DH, Hubel A.

Cytotherapy. 2015 Jan;17(1):38-45. doi: 10.1016/j.jcyt.2014.06.008. Epub 2014 Oct 24.

7.

Complement fragment 3a priming of umbilical cord blood progenitors: safety profile.

Brunstein CG, McKenna DH, DeFor TE, Sumstad D, Paul P, Weisdorf DJ, Ratajczak M, Laughlin MJ, Wagner JE.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1474-9. doi: 10.1016/j.bbmt.2013.07.016. Epub 2013 Jul 25.

8.

Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity.

Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, McKenna DH, Bromberg JS, Levine BL, Riley JL, June CH, Scheinberg P, Douek DC, Miller JS, Wagner JE, Blazar BR.

Sci Transl Med. 2011 May 18;3(83):83ra41. doi: 10.1126/scitranslmed.3001809.

9.

Interlaboratory assessment of a novel colony-forming unit assay: a multicenter study by the cellular team of Biomedical Excellence for Safer Transfusion (BEST) collaborative.

Nawrot M, McKenna DH, Sumstad D, McMannis JD, Szczepiorkowski ZM, Belfield H, Grassman E, Temples T, Nielsen D, Yuan N, Wognum B, Reems JA.

Transfusion. 2011 Sep;51(9):2001-5. doi: 10.1111/j.1537-2995.2011.03153.x. Epub 2011 May 13.

PMID:
21569039
10.

Shipping of therapeutic somatic cell products.

Whiteside TL, Griffin DL, Stanson J, Gooding W, McKenna D, Sumstad D, Kadidlo D, Gee A, Durett A, Lindblad R, Wood D, Styers D.

Cytotherapy. 2011 Feb;13(2):201-13. doi: 10.3109/14653249.2010.506507. Epub 2010 Aug 26.

PMID:
20795760
11.

CD34(+) cell selection using small-volume marrow aspirates: a platform for novel cell therapies and regenerative medicine.

McKenna DH Jr, Adams S, Sumstad D, Sumstad T, Kadidlo D, Gee AP, Durett A, Griffin D, Donnenberg A, Amrani D, Livingston D, Lindblad R, Wood D, Styers D.

Cytotherapy. 2010 Apr;12(2):170-7. doi: 10.3109/14653240903476446.

12.

Transfusion-associated graft-versus-host disease: a perspective from a cell therapy laboratory.

Hummon D, Zantek ND, Sumstad D, Miller JS, McKenna DH.

Transfusion. 2009 May;49(5):1018-9. doi: 10.1111/j.1537-2995.2009.02121.x. No abstract available.

PMID:
19426202
13.

A multicenter comparison study between the Endosafe PTS rapid-release testing system and traditional methods for detecting endotoxin in cell-therapy products.

Gee AP, Sumstad D, Stanson J, Watson P, Proctor J, Kadidlo D, Koch E, Sprague J, Wood D, Styers D, McKenna D, Gallelli J, Griffin D, Read EJ, Parish B, Lindblad R.

Cytotherapy. 2008;10(4):427-35. doi: 10.1080/14653240802075476.

14.

Loss of integrity of umbilical cord blood unit freezing bags: description and consequences.

Thyagarajan B, Berger M, Sumstad D, McKenna DH Jr.

Transfusion. 2008 Jun;48(6):1138-42. doi: 10.1111/j.1537-2995.2008.01688.x. Epub 2008 Apr 16.

PMID:
18422848
15.

Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience.

McKenna DH Jr, Sumstad D, Bostrom N, Kadidlo DM, Fautsch S, McNearney S, Dewaard R, McGlave PB, Weisdorf DJ, Wagner JE, McCullough J, Miller JS.

Transfusion. 2007 Mar;47(3):520-8.

PMID:
17319835
16.

Supplemental Content

Loading ...
Support Center